Eupraxia Pharmaceuticals (NASDAQ:EPRX) Research Coverage Started at Craig Hallum

Craig Hallum initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report issued on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $12.00 target price on the stock.

Several other equities research analysts have also recently weighed in on EPRX. RODMAN&RENSHAW raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw started coverage on Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock.

Eupraxia Pharmaceuticals Stock Up 2.8 %

Shares of Eupraxia Pharmaceuticals stock opened at $3.65 on Friday. The stock has a market cap of $130.12 million and a price-to-earnings ratio of -5.07. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $5.15. The company’s fifty day moving average is $3.13 and its 200 day moving average is $2.91.

Institutional Trading of Eupraxia Pharmaceuticals

Large investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter valued at about $37,000. Bank of Montreal Can lifted its stake in Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock valued at $178,000 after buying an additional 7,500 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth approximately $31,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.